#USA #Tucson #Sleep Apnea #Daybreak #University of Arizona

University of Arizona Launches Major Clinical Trial on Sleep Apnea Treatments

In a significant advancement in the field of sleep medicine, the University of Arizona has declared the launch of a groundbreaking clinical trial aimed at dissecting the effectiveness of the top three treatments for obstructive sleep apnea (OSA). This landmark study is backed by an impressive $14 million grant from the Patient-Centered Outcomes Research Institute (PCORI) and will involve 2,400 participants over the span of five years.

Study Overview

The trial will offer the most thorough head-to-head comparison to date of continuous positive airway pressure (CPAP) therapy, mandibular advancement devices (MAD), and a pharmacological combination of atomoxetine and oxybutynin. It will be helmed by Dr. Sairam Parthasarathy, a prominent sleep medicine expert and Director of the University of Arizona Center for Sleep, Circadian, and Neuroscience Research. With a holistic approach, the trial aims to track various metrics over a 12-month period, including daytime sleepiness, blood pressure levels, quality of life, and patient adherence to treatment.

The research will take place across four significant academic medical institutions: the University of Arizona, Stanford Medicine, the University of Maryland School of Medicine, and the University of Miami Miller School of Medicine.

Addressing Challenges in Sleep Medicine

Despite the significance of these treatments, one of the largest hindrances in sleep medicine today is ensuring patient access to appropriate therapies. Dr. Parthasarathy emphasizes the value of collaboration with Daybreak, a company renowned for its patient-centered delivery model. Their infrastructure aims to streamline the treatment process, maintaining essential clinical oversight along the way. This collaboration highlights the commitment to improving access for patients enrolled in the oral appliance therapy arm of the study.

Daybreak will provide its FDA-cleared mandibular advancement device therapy along with comprehensive patient support services to participants across all trial sites, thereby ensuring consistent treatment access. This nationwide care model is uniquely structured to minimize operational discrepancies while delivering a uniform experience to patients, irrespective of geographic variances.

Potential Impact on Clinical Practice

The implications of this study are substantial, with the potential to reshape the way sleep apnea is treated nationally for years to come. Van Morgan, CFO and Co-founder of Daybreak, commented on the honor and responsibility of facilitating participant access to treatment during the study. Findings from this trial are expected to play a crucial role in informing clinical practice guidelines and treatment protocols, ultimately guiding patients and healthcare providers alike in making more informed healthcare choices regarding OSA treatments.

Summary

As we anticipate the outcomes of this extensive clinical trial, it holds promise not just for participants, but for the broader medical community aiming to improve sleep apnea treatment pathways. The collaboration reflects a commitment towards evidential, patient-centered approaches in the growing field of sleep medicine, potentially paving the way for enhanced health outcomes.

For additional inquiries regarding the study, interested parties may contact Heidi Erickson at the University of Arizona’s Clinical Research Department.